Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the … Read more
Rallybio Corp (RLYB) - Total Liabilities
Latest total liabilities as of September 2025: $4.63 Million USD
Based on the latest financial reports, Rallybio Corp (RLYB) has total liabilities worth $4.63 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rallybio Corp - Total Liabilities Trend (2019–2024)
This chart illustrates how Rallybio Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Rallybio Corp Competitors by Total Liabilities
The table below lists competitors of Rallybio Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Precot Limited
NSE:PRECOT
|
India | ₹4.75 Billion |
|
AB Klaipedos nafta
F:XIC
|
Germany | €362.64 Million |
|
Chen Nan Iron Wire Co.,Ltd
TWO:2071
|
Taiwan | NT$1.16 Billion |
|
Nahar Spinning Mills Limited
NSE:NAHARSPING
|
India | ₹9.46 Billion |
|
Arena Bilgisayar Sanayi ve Ticaret AS
IS:ARENA
|
Turkey | TL11.85 Billion |
|
Phenom Resources Corp
OTCQX:PHNMF
|
USA | $180.24K |
|
Cosmax Nbt Inc
KQ:222040
|
Korea | ₩248.46 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Rallybio Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rallybio Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rallybio Corp (2019–2024)
The table below shows the annual total liabilities of Rallybio Corp from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.45 Million | -31.60% |
| 2023-12-31 | $9.44 Million | -15.13% |
| 2022-12-31 | $11.12 Million | +68.89% |
| 2021-12-31 | $6.58 Million | +12.43% |
| 2020-12-31 | $5.86 Million | +23.34% |
| 2019-12-31 | $4.75 Million | -- |